Abstract:The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein-degrader-ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein-protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.

Towards Targeted Protein Degradation in - depletion of the essential GroEL protein using CLIPPERs

Identification of New Degrons in Streptococcus Mutans Reveals a Novel Strategy for Engineering Targeted, Controllable Proteolysis.

Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

Degradome analysis to identify direct protein substrates of small-molecule degraders

Targeted protein degradation: from mechanisms to clinic

Engineering an SspB-mediated degron for novel controllable protein degradation

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation in mycobacteria uncovers antibacterial effects and potentiates antibiotic efficacy

Degron-Controlled Protein Degradation in Escherichia coli : New Approaches and Parameters

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development

Targeted Protein Degradation: Principles, Strategies, and Applications

Targeted protein degradation via intramolecular bivalent glues

Confounding factors in targeted degradation of short-lived proteins

Recent advances in targeted protein degraders as potential therapeutic agents

Peptidic degron for IMiD-induced degradation of heterologous proteins

Targeting the Undruggables ---- the Power of Protein Degraders

A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

Protein degradation by small tag artificial bacterial E3 ligase